Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Teleflex (TFX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report), Teleflex (TFX – Research Report) and Aurinia Pharmaceuticals (AUPH – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Pharmaceuticals (RYTM)
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Rhythm Pharmaceuticals, with a price target of $139.00. The company’s shares closed last Thursday at $99.55.
According to TipRanks.com, Stringer is a 5-star analyst with an average return of
Rhythm Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $143.83, implying a 39.3% upside from current levels. In a report issued on February 18, RBC Capital also initiated coverage with a Buy rating on the stock with a $145.00 price target.
See the top stocks recommended by analysts >>
Teleflex (TFX)
In a report released today, Michael Matson from Needham maintained a Buy rating on Teleflex, with a price target of $147.00. The company’s shares closed last Thursday at $119.64.
According to TipRanks.com, Matson is a 2-star analyst with an average return of
Teleflex has an analyst consensus of Hold, with a price target consensus of $127.00.
Aurinia Pharmaceuticals (AUPH)
TD Cowen analyst Stacy Ku maintained a Buy rating on Aurinia Pharmaceuticals today and set a price target of $17.00. The company’s shares closed last Thursday at $13.99.
According to TipRanks.com, Ku is a 4-star analyst with an average return of
Aurinia Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $16.50.
